Bayer puts $2.2 billion behind US pharma manufacturing
Subscribe to our free newsletter today to keep up to date with the latest manufacturing news.
Bayer plans to invest $2.2 billion in a new pharmaceutical manufacturing campus in New Albany, Ohio, as the German group expands production in one of its most important markets.
The site is expected to create about 600 permanent jobs and 1,500 construction jobs. Bayer plans to manufacture both drug substances and finished medicines there, with initial production focused on oncology, cardiovascular and renal treatments.
The first manufacturing module is scheduled to begin operations in 2031. A second module is planned for 2034.
The timetable shows that Bayer is planning far beyond current demand. The company is committing capital to US production years before the site reaches full operation. The decision reflects a broader change in pharmaceutical manufacturing, where market growth, new drug portfolios, supply security and government policy are all affecting investment decisions.
The project follows more than $7 billion in US pharmaceutical research, development and manufacturing spending by Bayer during the past five years.
The US market gives Bayer a strong reason to manufacture locally
The commercial case for expanding US capacity is becoming stronger for global drugmakers.
Bayer described the US as its fastest-growing pharmaceutical market when it announced the Ohio project. Its 2025 results show why.
North American pharmaceutical sales reached €5.84 billion in 2025, up 19.7% after adjusting for currency and portfolio changes. Bayer’s overall pharmaceutical sales rose 1.7% on the same basis to €17.83 billion.
That difference shows how important North American growth has become to the company.
It also comes as Bayer manages falling sales from some older medicines while demand rises for newer products.
Sales of prostate cancer medicine Nubeqa rose 62.4% on a currency and portfolio-adjusted basis in 2025, reaching €2.39 billion. Bayer said growth was particularly strong in the US and Europe.
Xarelto moved in the other direction. Sales of the anticoagulant fell 31.6% on the same basis as patent expirations and generic competition reduced demand outside the US.
The shift shows why manufacturing plans cannot rely only on today’s best-selling products. Capacity built now must support the medicines companies expect to sell several years from now.
Bayer has said the Ohio site will initially serve its oncology, cardiovascular and renal portfolio. Those areas include products that could account for a larger share of future pharmaceutical revenue.
Tariffs add pressure, but the manufacturing shift runs deeper
US trade policy is adding another incentive for pharmaceutical groups to increase domestic production.
The Trump administration has used pharmaceutical tariffs as part of a broader effort to encourage more manufacturing in the US. That policy forms part of the backdrop to Bayer’s announcement.
However, it does not fully explain an investment that will not begin producing medicines until 2031.
Bayer has presented the New Albany development as part of a longer US growth plan. The company already operates pharmaceutical sites in California, Massachusetts, North Carolina and Pennsylvania, alongside its US pharmaceutical headquarters in New Jersey.
There are broader business reasons to keep more production close to a major market.
Local capacity can reduce reliance on long international supply chains. It can also give manufacturers more control over production planning when demand changes or transport networks face disruption.
The design of Bayer’s Ohio campus reflects that approach. The company plans to combine drug-substance and finished-product manufacturing at one location while using digital systems and automation.
Bringing more stages of production together may also help Bayer coordinate manufacturing as medicines move from development into commercial use.
Policy may influence the timing of investment. The size of the US pharmaceutical market gives companies a longer-term reason to keep adding domestic capacity.
Bayer is building capacity for a market years ahead
The development schedule is one of the most important parts of the project.
Bayer does not expect the first module, focused on drug-substance manufacturing, to begin operating until 2031. A second module for finished pharmaceutical products is due to follow in 2034.
The company is therefore investing against expectations for its future portfolio rather than current production needs alone.
The modular design should give Bayer more flexibility over how capacity is added. Pharmaceutical products can take years to move through clinical development and regulatory approval, so manufacturers face a difficult balance between building too early and waiting too long.
Adding capacity in stages gives Bayer more room to adjust production as demand changes across different medicines.
That approach is becoming more important as pharmaceutical portfolios change. Established drugs can lose patent protection while newer treatments move into larger patient groups.
Bayer’s own results show that transition. Growth in medicines such as Nubeqa and Kerendia is offsetting some of the pressure from products including Xarelto and Eylea.
The Ohio facility will support that shift by adding manufacturing capacity for products expected to play a larger role in Bayer’s future business.
The wider point for pharmaceutical manufacturers is that US investment decisions are being shaped by several forces at once. Trade policy is one factor. Market demand, pipeline changes, supply reliability and automation also matter.
A facility that is not scheduled to begin production until 2031 also puts the current policy debate into context.
Trade rules may change before the first medicines leave Bayer’s Ohio site. The company is still committing $2.2 billion.
That suggests the move toward greater US pharmaceutical manufacturing is likely to extend beyond the current policy cycle.
Source:
Bayer
